ARTICLE | Clinical News
Abstral fentanyl regulatory update
June 7, 2010 7:00 AM UTC
FDA extended by three months the PDUFA date of June 4 for an NDA from ProStrakan for Abstral fentanyl to treat breakthrough cancer pain in patients already receiving opioid treatment. The company said...